alexa Editor - Jia-Long Fang | Shanghai Medical University | 23191

Annals of Infections and Antibiotics
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Jia-Long Fang

Jia-Long Fang
Jia-Long Fang
Division of Biochemical Toxicology
National Center for Toxicological Research
3900 NCTR Road,
HFT-110 Jefferson,
AR 72079
P.R. China

Biography

Dr. Fang is a Research Biologist at the Division of Biochemical Toxicology, National Center for Toxicological Research/FDA. Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has been the principal investigator on many approved NCTR protocols that address the biological mechanisms underlying the toxicities of drugs and chemicals. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.

Dr. Fang received a Bachelor’s degree in Public Health in 1985 from Shanghai Medical University and a Master’s degree in Toxicology in 1990 from Chinese Academy of Preventive Medicine in China. In 1997, Dr. Fang received his Ph.D. in Molecular Epidemiology from the renowned Karolinska Institute in Stockholm, Sweden. He joined the NCTR/FDA as an ORISE Postdoctoral Fellow in 1997 and rejoined the NCTR/FDA as a Staff Fellow in 2004. Dr. Fang is author/co-author of 56 publications including peer-reviewed articles and/or scientific reports.

Research Interest

Dr. Fang has over twenty-years of research experience in biochemical carcinogenesis and toxicology. He has designed, developed, and executed in vitro and in vivo research investigations that address the biological mechanisms underlying the toxicities of drugs and chemicals. Throughout his career at NCTR, Dr. Fang’s research has been focused on the biological mechanisms of action underlying the toxicity of chemicals regulated by, or of interest to, the FDA, such as ethanol, urethane, tolvaptan, and antiretroviral drugs, including zidovudine, lamivudine, and nevirapine. More recently, Dr. Fang has been leading a research team to investigate the toxicities of topically applied triclosan. His research is highly relevant to the FDA’s mission and has direct scientific impact on the regulatory responsibilities of the FDA.

Leave Your Message 24x7
Top